Interestingly, this study provided also evidence that prostate cancer patients with aberrations in Fanconi anemia-complex genes or in ATM serine/threonine kinase displayed markedly longer treatment responses to carboplatin than did patients without defects in genes encoding DNA repair proteins [73]. Here, ATM is linked to prostate carcinoma.